MilliporeSigma Capabilities Update August 2026: Nanoparticles

Bringing lipid-based therapies from early development to commercialization requires specialized expertise, scalable infrastructure, and coordinated support. MilliporeSigma’s end-to-end CDMO capabilities span lipid manufacturing, lipid nanoparticle formulation, process development, analytical testing, aseptic fill and finish, and supply chain management. Centers of excellence in Darmstadt, Schaffhausen, and Indianapolis support programs from preclinical formulation screening through clinical and commercial manufacturing. Available capabilities include flexible manufacturing scales, multiple formulation and mixing technologies, lyophilization services, GMP operations, and adaptable vial-filling processes.

Learn how an integrated global network, decades of lipid and drug product experience, and established regulatory expertise can help you streamline technology transfer.